Skip to main content

Advertisement

Table 3 Adverse events, overall and most common (safety analysis set)

From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

 EnsifentrinePlacebo (N = 79)
0.75 mg (N = 81)1.5 mg (N = 81)3 mg (N = 82)6 mg (N = 80)
Any adverse event27 (33)36 (44)29 (35)29 (36)31 (39)
 Headache4 (5)4 (5)7 (9)4 (5)3 (4)
 Worsening of COPD symptoms5 (6)5 (6)3 (4)3 (4)6 (8)
 Cough4 (5)4 (5)6 (7)1 (1)1 (1)
 Nasopharyngitis2 (2)4 (5)4 (5)5 (6)7 (9)
 Hypertension2 (2)1 (1)4 (5)3 (4)1 (1)
 Nausea3 (4)2 (2)2 (2)02 (3)
 Dyspnoea3 (4)1 (1)1 (1)1 (1)5 (6)
 Productive cough03 (4)1 (1)00
Any treatment-related adverse event8 (10)11 (14)12 (15)8 (10)10 (13)
 Cough2 (2)1 (1)4 (5)1 (1)1 (1)
 Dyspnoea1 (1)0003 (4)
 Productive cough03 (4)000
Any severe adverse event4 (5)1 (1)2 (2)1 (1)2 (3)
Any serious adverse event2 (2)2 (2)1 (1)1 (1)1 (1)
Any serious treatment-related adverse event1 (1)1 (1)000
Any adverse event leading to drug discontinuation6 (7)1 (1)4 (5)2 (3)2 (3)
Any adverse event leading to death01 (1)01 (1)0
  1. Data are n (%). The most common adverse events and drug-related adverse events are those reported in more than two patients in any group